Home › Trial NCT03975231
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
- Trial IDNCT03975231
- StatusSuspended
- PhasePhase 1
- Study typeInterventional
- SponsorCity of Hope Medical Center
- Enrollment6
- Start date2020-09-14
- ConditionsBRAF NP_004324.2:p.V600E · BRAF V600K Mutation Present · Thyroid Gland Anaplastic Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.